Cardiff Oncology Inc (CRDF) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: -$4.6M

CRDF ranks #4451 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

107 institutions disclose a position in CRDF, but none treat it as a major bet — even Pfizer Inc, its most concentrated holder, allocates just 1.8% of its own portfolio to it.

Assenagon Asset Management S.A. has trimmed its CRDF position for two straight quarters, cutting it by $27.6K while still holding $81.4K.

CRDF is down 7.2% today, and institutions have been net sellers of $4.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CRDF reported a net loss of $40.1M over the trailing twelve months.

• Not yet profitable — net loss of $40.1M over the trailing twelve months
• Revenue declined 7.0% year over year
• Net income improved year over year, from -$51.0M to -$40.1M
• Operating cash flow was negative, using $37.9M in cash
• Current ratio of 3.67x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.36x equity — within a conventional range